Lyra Therapeutics (NASDAQ:LYRA) reported quarterly losses of $(0.13) per share which beat the analyst consensus estimate of $(0.15) by 13.33 percent. This is a 62.86 percent increase over losses of $(0.35) per share from the same period last year. The company reported quarterly sales of $183.00 thousand which missed the analyst consensus estimate of $240.00 thousand by 23.75 percent. This is a 65.60 percent decrease over sales of $532.00 thousand the same period last year.